The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 748K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

25 articles for HR Kim


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Replacing the terminal piperidine in ceritinib with aliphatic amines confers activities against crizotinib-resistant mutants including G1202R.EBI
Korea Research Institute of Chemical Technology
Novel 2,4-diaminopyrimidines bearing tetrahydronaphthalenyl moiety against anaplastic lymphoma kinase (ALK): Synthesis, in vitro, ex vivo, and in vivo efficacy studies.EBI
Chungbuk National University
Synthesis and evaluation of novel 2,4-diaminopyrimidines bearing bicyclic aminobenzazepines for anaplastic lymphoma kinase (ALK) inhibitor.EBI
Korea Research Institute of Chemical Technology
Discovery of substituted 6-pheny-3H-pyridazin-3-one derivatives as novel c-Met kinase inhibitors.EBI
Sungkyunkwan University
Design and synthesis of novel 3-(benzo[d]oxazol-2-yl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine derivatives as selective G-protein-coupled receptor kinase-2 and -5 inhibitors.EBI
Korea Research Institute of Chemical Technology
Synthesis and structure-activity relationship of aminopyridines with substituted benzoxazoles as c-Met kinase inhibitors.EBI
Korea Research Institute of Chemical Technology
Design and synthesis of 3-(4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridin-2-yl)-1H-quinolin-2-ones as VEGFR-2 kinase inhibitors.EBI
Korea Research Institute of Chemical Technology
Discovery of aminopyridines substituted with benzoxazole as orally active c-Met kinase inhibitors.EBI
Korea Research Institute of Chemical Technology
Design and synthesis of triazolopyridazines substituted with methylisoquinolinone as selective c-Met kinase inhibitors.EBI
Korea Research Institute of Chemical Technology
Design, synthesis, and evaluation of 2-aryl-7-(3',4'-dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidines as novel PDE-4 inhibitors.EBI
Korea Research Institute of Chemical Technology
Structure-Activity Relationships of Truncated 1'-Homologated Carbaadenosine Derivatives as New PPARγ/δ Ligands: A Study on Sugar Puckering Affecting Binding to PPARs.EBI
Seoul National University
Discovery of 2-aminoquinolone acid derivatives as potent inhibitors of SARS-CoV-2.EBI
Seoul National University
Covalent Small Molecule Immunomodulators Targeting the Protease Active Site.EBI
National Cancer Institute
Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors.EBI
Korea Research Institute of Chemical Technology
Identification of 6'-β-fluoro-homoaristeromycin as a potent inhibitor of chikungunya virus replication.EBI
Seoul National University
Design, Synthesis, and Anti-RNA Virus Activity of 6'-Fluorinated-Aristeromycin Analogues.EBI
Seoul National University
Synthesis and biological evaluation of 3-acyl-2-phenylamino-1,4-dihydroquinolin-4(1H)-one derivatives as potential MERS-CoV inhibitors.EBI
Korea Research Institute of Chemical Technology
Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.EBI
Seoul National University
BACE1 inhibitory activity and molecular docking analysis of meroterpenoids from Sargassum serratifolium.EBI
Pukyong National University
Novel 2,4-diaminopyrimidines bearing fused tricyclic ring moiety for anaplastic lymphoma kinase (ALK) inhibitor.EBI
University of Science & Technology
Ethynyl derivativesBDB
Hoffmann-La Roche
Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesBDB
Abbvie
Bicyclic aryl and heteroaryl sodium channel inhibitorsBDB
Amgen
TRPV1 antagonistsBDB
TBA